Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.60
-0.12-6.98%
Last update: Oct 19, 6:08 AM
$1.62
-0.1-5.81%
Autolus Therapeutics PLC (AUTL) Stock Price, Quote, News & History
AUTLNASDAQ
| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5,...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Autolus Therapeutics (NASDAQ:AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Autolus Therapeutics has a consensus price target of $9.14.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $1.62 last updated October 19, 2026 at 6:08 AM EDT.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
